<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00928720</url>
  </required_header>
  <id_info>
    <org_study_id>14203</org_study_id>
    <nct_id>NCT00928720</nct_id>
  </id_info>
  <brief_title>Cranial Electrical Stimulation Effects on Symptoms in Persons With Fibromyalgia</brief_title>
  <official_title>Cranial Electrical Stimulation Effects on Symptoms in Persons With Fibromyalgia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Virginia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Virginia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effects of mild cranial electrical stimulation
      on pain, fatigue, sleep disturbances, perceived stress, blood pressure, and functional status
      in persons with fibromyalgia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Central pain networks in the brain are dysregulated in persons with fibromyalgia (FM). Thus,
      the investigators propose that cranial electrical stimulation (CES) that works on the brain
      may ameliorate symptoms of FM by interacting with the central pain networks. The specific
      aims of this randomized, controlled, three-group pilot study design are to: (1) determine
      differences in pain over time between the active CES, sham device, and usual care (UC)
      groups; (2) explore differences in brain activity in pain processing regions (i.e.,
      cingulate, insula, prefrontal and somatosensory cortices, amygdala, and thalamus) between the
      active CES, sham device, and UC groups in a subset of 12 participants (6 in each device
      group); (3) determine the effects of CES on other symptoms (fatigue, sleep disturbances,
      depression, perceived stress) and functional status, and blood pressure over time between the
      active CES, sham device, and UC groups; and (4) determine the amount of influence that
      selected psychological factors (negative affect, catastrophizing, and other personality
      characteristics) have on group differences in pain, other symptoms, functional status, and
      brain activity.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain Intensity Using Numeric Rating Scale</measure>
    <time_frame>week 8</time_frame>
    <description>A Numeric Rating Scale ranging from 0 (no pain) to 10 (worst pain imaginable) to capture present pain intensity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fatigue Using Lee's Fatigue Scale</measure>
    <time_frame>at baseline and weekly over 8 weeks</time_frame>
    <description>A Numeric Rating Scale ranging from 0-10 to capture present levels of fatigue using the fatigue subscale of Lee's Fatigue Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep Disturbances and Sleep Quality Using Wrist Actigraph and Sleep Diary, General Sleep Disturbance Scale, and Pittsburgh Sleep Quality Index</measure>
    <time_frame>wear actigraph and keep sleep diary for 96 hrs at baseline and weeks 4 and 8; GSDS at baseline and weekly over 8 weeks; PSQI at baseline and weeks 4 and 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depression Using the CES-D</measure>
    <time_frame>at baseline and weekly over 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perceived Stress Using Numeric Rating Scale and the Daily Stress Inventory</measure>
    <time_frame>at baseline and weekly over 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Status Using the Fibromyalgia Index Questionnaire</measure>
    <time_frame>at baseline and weekly over 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Pressure Using the Omron HEM-711DLX Upper Arm Blood Pressure Monitor</measure>
    <time_frame>at baseline and daily over 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in Brain Activity in Pain Processing Regions Between the Active CES and Sham Device Groups in a Subset of 12 Participants (6 in Each Device Group) Using fMRI</measure>
    <time_frame>at baseline and week 8</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">57</enrollment>
  <condition>Fibromyalgia</condition>
  <arm_group>
    <arm_group_label>CES device</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will use the device for 60 minutes each day for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham device</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Participants will use the device for 60 continuous minutes each day for 8 weeks. The sham device will look the same as the active CES device; however, no electrical stimulation will be present in the sham device.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual care alone</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No intervention; participants will receive usual medical care</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CES device</intervention_name>
    <description>Participants will use the device for 60 continuous minutes each day for 8 weeks. The CES device will be preset at the factory to provide a maximum of 60 minutes of modified square-wave biphasic stimulation at 0.5 Hz and 100ÂµA, the lowest setting that has been used in previous studies with patients with FM.</description>
    <arm_group_label>CES device</arm_group_label>
    <other_name>Alpha-Stim</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>sham device</intervention_name>
    <description>The sham device will look the same as the active CES (Alpha-Stim); however, no electrical stimulation will be present in the sham device.</description>
    <arm_group_label>Sham device</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  meet the diagnostic criteria for FM established by the American College of
             Rheumatology

          -  have initial pain level equal to or greater than 3 on a NRS 0-10

          -  have stable medication use related to FM for at least 4 weeks

          -  be able to read, write, and understand the English language

        Exclusion Criteria (all participants):

          -  pregnant or breastfeeding

          -  epilepsy or history of seizures

          -  presence of pacemakers and/or other implanted devices

        Exclusion Criteria (subset of 12 participants who wil have fMRIs):

          -  conditions that would not permit an fMRI (e.g., certain types of metal or metallic
             objects in body, diaphragm or intrauterine device, dermal patches, ear or eye
             implants, implanted electrical stimulators, artificial heart valve, implanted catheter
             or tube, tattoos, claustrophobia; or weight more than 275 lbs)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ann G Taylor, EdD, RN</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Virginia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Virginia Center for the Study of Complementary and Alternative Therapies</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 24, 2009</study_first_submitted>
  <study_first_submitted_qc>June 25, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 26, 2009</study_first_posted>
  <results_first_submitted>June 5, 2014</results_first_submitted>
  <results_first_submitted_qc>August 11, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 13, 2014</results_first_posted>
  <last_update_submitted>August 11, 2014</last_update_submitted>
  <last_update_submitted_qc>August 11, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 13, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Virginia</investigator_affiliation>
    <investigator_full_name>Ann G Taylor</investigator_full_name>
    <investigator_title>Professor of Nursing</investigator_title>
  </responsible_party>
  <keyword>fibromyalgia</keyword>
  <keyword>pain</keyword>
  <keyword>sleep disturbance</keyword>
  <keyword>fatigue</keyword>
  <keyword>depression</keyword>
  <keyword>functional magnetic resonance imaging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibromyalgia</mesh_term>
    <mesh_term>Myofascial Pain Syndromes</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>CES Device</title>
          <description>cranial electrical stimulation (CES) device (Alpha-Stim): Participants will use the device for 60 continuous minutes each day for 8 weeks. The CES device will be preset at the factory to provide a maximum of 60 minutes of modified square-wave biphasic stimulation at 0.5 Hz and 100ÂµA, the lowest setting that has been used in previous studies with patients with FM.</description>
        </group>
        <group group_id="P2">
          <title>Sham Device</title>
          <description>Participants will use the device for 60 continuous minutes each day for 8 weeks. The sham device will look the same as the active CES device; however, no electrical stimulation will be present in the sham device.
sham device: The sham device will look the same as the active CES (Alpha-Stim); however, no electrical stimulation will be present in the sham device.</description>
        </group>
        <group group_id="P3">
          <title>Usual Care Alone</title>
          <description>No intervention; usual medical care for fibromyalgia</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>CES Device</title>
          <description>cranial electrical stimulation (CES) device (Alpha-Stim): Participants will use the device for 60 continuous minutes each day for 8 weeks. The CES device will be preset at the factory to provide a maximum of 60 minutes of modified square-wave biphasic stimulation at 0.5 Hz and 100ÂµA, the lowest setting that has been used in previous studies with patients with FM.</description>
        </group>
        <group group_id="B2">
          <title>Sham Device</title>
          <description>Participants will use the device for 60 continuous minutes each day for 8 weeks. The sham device will look the same as the active CES device; however, no electrical stimulation will be present in the sham device.
sham device: The sham device will look the same as the active CES (Alpha-Stim); however, no electrical stimulation will be present in the sham device.</description>
        </group>
        <group group_id="B3">
          <title>Usual Care Alone</title>
          <description>No intervention; participants will received usual medical care for fibromyalgia</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="17"/>
            <count group_id="B2" value="14"/>
            <count group_id="B3" value="15"/>
            <count group_id="B4" value="46"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.9" spread="10.6"/>
                    <measurement group_id="B2" value="51.5" spread="10.9"/>
                    <measurement group_id="B3" value="48.6" spread="9.8"/>
                    <measurement group_id="B4" value="50.8" spread="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pain Numeric Rating Scale</title>
          <description>A Numeric Rating Scale to capture average pain. The scales ranges from 0 (no pain) to 10 (worst pain imaginable).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.8" spread="1.9"/>
                    <measurement group_id="B2" value="5.7" spread="1.6"/>
                    <measurement group_id="B3" value="6.0" spread="2.1"/>
                    <measurement group_id="B4" value="5.8" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fatigue</title>
          <description>A Numeric Rating Scale to capture present fatigue. The scales ranges from 0 (no pain) to 10 (worst fatigue imaginable).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.12" spread="1.89"/>
                    <measurement group_id="B2" value="6.66" spread="2.0"/>
                    <measurement group_id="B3" value="6.85" spread="1.74"/>
                    <measurement group_id="B4" value="6.53" spread="1.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fibromyalgia impact</title>
          <description>The Fibromyalgia Impact Questionnaire is a brief assessment and evaluation instrument consisting of 19 items to measure patient status, progress, and outcomes of patients with fibromyalgia over the past week. The measure is self-administered and takes approximately 5 minutes to complete. Total scores range from 0 to 80, with 0 indicating no impact and 80 indicating maximum impact, thus a higher score indicating more negative impact.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.36" spread="18.2"/>
                    <measurement group_id="B2" value="65.98" spread="17.9"/>
                    <measurement group_id="B3" value="66.31" spread="16.9"/>
                    <measurement group_id="B4" value="64.51" spread="17.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Depression</title>
          <description>The Center for Epidemiological Studies-Depression (CES-D) scale is a 20-item measure that asks the individual to rate how often over the past week s/he has experienced symptoms associated with depression, such as restless sleep, poor appetite, and feeling lonely. Response options range from 0 to 3 for each item. Scores range from 0 to 60, with high scores indicating greater depressive symptoms. The CES-D also provides cutoff scores (e.g., 16 or greater) that aid in identifying individuals at risk for clinical depression.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.9" spread="11.8"/>
                    <measurement group_id="B2" value="29.5" spread="13.7"/>
                    <measurement group_id="B3" value="24.1" spread="14.2"/>
                    <measurement group_id="B4" value="26.0" spread="13.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>General sleep disturbance</title>
          <description>The General Sleep Disturbance Scale (GSDS) is a subjective measure of sleep disturbance that contains 21 items rating the frequency of specific sleep problems during the past week from 0 to 7. Each item is rated on a numeric rating scale ranging from 0 to 7 and the total 21 items are summed to calculate total score ranging from 0 (no disturbance) to 147 (extreme disturbance); higher scores indicate greater sleep disturbances.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.75" spread="0.94"/>
                    <measurement group_id="B2" value="4.01" spread="0.80"/>
                    <measurement group_id="B3" value="3.6" spread="0.86"/>
                    <measurement group_id="B4" value="3.8" spread="0.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Daily stress impact</title>
          <description>The Daily Stress Inventory is a 58-item measure designed to quantify individualsâ perceived daily stress by rating the stressfulness of the events identified on a Likert-type scale from 1 to 7. Three daily scores are derived for each individual: (1) number of events that are scored as having occurred (Frequency), (2) sum of the total of the impact rating of these events (Summary, and (3) average impact rating of the events (the AIR, which is obtained by dividing the Summary score by the Frequency Score). Higher the scores the worse the individualâs stress level.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.86" spread="1.2"/>
                    <measurement group_id="B2" value="3.05" spread="1.1"/>
                    <measurement group_id="B3" value="3.39" spread="1.3"/>
                    <measurement group_id="B4" value="3.44" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pain Intensity Using Numeric Rating Scale</title>
        <description>A Numeric Rating Scale ranging from 0 (no pain) to 10 (worst pain imaginable) to capture present pain intensity</description>
        <time_frame>week 8</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CES Device</title>
            <description>cranial electrical stimulation (CES) device (Alpha-Stim): Participants will use the device for 60 continuous minutes each day for 8 weeks. The CES device will be preset at the factory to provide a maximum of 60 minutes of modified square-wave biphasic stimulation at 0.5 Hz and 100ÂµA, the lowest setting that has been used in previous studies with patients with FM.</description>
          </group>
          <group group_id="O2">
            <title>Sham Device</title>
            <description>Participants will use the device for 60 continuous minutes each day for 8 weeks. The sham device will look the same as the active CES device; however, no electrical stimulation will be present in the sham device.
sham device: The sham device will look the same as the active CES (Alpha-Stim); however, no electrical stimulation will be present in the sham device.</description>
          </group>
          <group group_id="O3">
            <title>Usual Care Alone</title>
            <description>No intervention; participants will receive usual medical care for fibromyalgia</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Intensity Using Numeric Rating Scale</title>
          <description>A Numeric Rating Scale ranging from 0 (no pain) to 10 (worst pain imaginable) to capture present pain intensity</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.12" spread="1.69"/>
                    <measurement group_id="O2" value="6.36" spread="2.11"/>
                    <measurement group_id="O3" value="6.62" spread="1.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fatigue Using Lee's Fatigue Scale</title>
        <description>A Numeric Rating Scale ranging from 0-10 to capture present levels of fatigue using the fatigue subscale of Lee's Fatigue Scale</description>
        <time_frame>at baseline and weekly over 8 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sleep Disturbances and Sleep Quality Using Wrist Actigraph and Sleep Diary, General Sleep Disturbance Scale, and Pittsburgh Sleep Quality Index</title>
        <time_frame>wear actigraph and keep sleep diary for 96 hrs at baseline and weeks 4 and 8; GSDS at baseline and weekly over 8 weeks; PSQI at baseline and weeks 4 and 8</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Depression Using the CES-D</title>
        <time_frame>at baseline and weekly over 8 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Perceived Stress Using Numeric Rating Scale and the Daily Stress Inventory</title>
        <time_frame>at baseline and weekly over 8 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Functional Status Using the Fibromyalgia Index Questionnaire</title>
        <time_frame>at baseline and weekly over 8 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Blood Pressure Using the Omron HEM-711DLX Upper Arm Blood Pressure Monitor</title>
        <time_frame>at baseline and daily over 8 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Differences in Brain Activity in Pain Processing Regions Between the Active CES and Sham Device Groups in a Subset of 12 Participants (6 in Each Device Group) Using fMRI</title>
        <time_frame>at baseline and week 8</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>CES Device</title>
          <description>cranial electrical stimulation (CES) device (Alpha-Stim): Participants will use the device for 60 continuous minutes each day for 8 weeks. The CES device will be preset at the factory to provide a maximum of 60 minutes of modified square-wave biphasic stimulation at 0.5 Hz and 100ÂµA, the lowest setting that has been used in previous studies with patients with FM.</description>
        </group>
        <group group_id="E2">
          <title>Sham Device</title>
          <description>Participants will use the device for 60 continuous minutes each day for 8 weeks. The sham device will look the same as the active CES device; however, no electrical stimulation will be present in the sham device.
sham device: The sham device will look the same as the active CES (Alpha-Stim); however, no electrical stimulation will be present in the sham device.</description>
        </group>
        <group group_id="E3">
          <title>Usual Care Alone</title>
          <description>No intervention; participants will receive usual medical care for fibromyalgia</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ann Gill Taylor, Professor Nursing</name_or_title>
      <organization>University of Virginia School of Nursing</organization>
      <phone>434-924-0113</phone>
      <email>agt@virginia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

